Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program - 16/11/11
, John G.F. Cleland, MD b, j, Stuart J. Pocock, PhD a, j, Marc A. Pfeffer, MD, PhD c, j, Karl Swedberg, MD, PhD d, j, Christopher B. Granger, MD e, j, John J.V. McMurray, MD f, j, Eric L. Michelson, MD g, j, Jan Östergren, MD, PhD h, j, Salim Yusuf, MD, DPhil i, jRésumé |
Background |
Conventional composite outcomes in heart failure (HF) trials, for example, time to cardiovascular death or first HF hospitalization, have recognized limitations. We propose an alternative outcome, days alive and out of hospital (DAOH), which incorporates mortality and all hospitalizations into a single measure. A refinement, the patient journey, also uses functional status (New York Heart Association [NYHA] class) measured during follow-up. The CHARM program is used to illustrate the methodology.
Methods |
CHARM randomized 7,599 patients with symptomatic HF to placebo or candesartan, with median follow-up of 38 months. We related DAOH and percent DAOH (ie, percentage of time spent alive and out of hospital) to treatment using linear regression adjusting for follow-up time.
Results |
Mean increase in DAOH for patients on candesartan versus placebo was 24.1 days (95% CI 9.8-38.3 days, P < .001). The corresponding mean increase in percent DAOH was 2.0% (95% CI 0.8%-3.1%, P < .001). These findings were dominated by reduced mortality (23 days) but enhanced by reduced time in hospital (1 day). Percent time spent in hospital because of HF was reduced by 0.10% (95% CI 0.04%-0.14%, P < .001). The patient journey analysis showed that patients in the candesartan group spent more follow-up time in NYHA classes I and II and less in NYHA class IV.
Conclusions |
Days alive and out of hospital, especially percent DAOH, provide a valuable tool for summarizing the overall absolute treatment effect on mortality and morbidity. In future HF trials, percent DAOH can provide a useful alternative perspective on the effects of treatment.
Le texte complet de cet article est disponible en PDF.Plan
| Robert O. Bonow, MD, served as guest editor for this article. |
|
| RCT reg no. NCT00634400. |
|
| Clinical Trial Registration: NCT00634400. |
Vol 162 - N° 5
P. 900-906 - novembre 2011 Retour au numéro
Article précédent
- Myeloperoxidase in the diagnosis of acute coronary syndromes: The importance of spectrum
- W. Frank Peacock, John Nagurney, Robert Birkhahn, Adam Singer, Nathan Shapiro, Judd Hollander, Ted Glynn, Richard Nowak, Basmah Safdar, Chadwick Miller, Mary Peberdy, Francis Counselman, Abhinav Chandra, Joshua Kosowsky, James Neuenschwander, Jon Schrock, Stephen Plantholt, Elizabeth Lewandrowski, Vance Wong, Ken Kupfer, Deborah Diercks
- Long-term clinical outcome in patients with small vessel disease treated with drug-eluting versus bare-metal stenting
- Etienne Puymirat, Fabio Mangiacapra, Aaron Peace, Faisal Sharif, Micaela Conte, Jozef Bartunek, Marc Vanderheyden, William Wijns, Bernard de Bruyne, Emanuele Barbato
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?